Hindawi Publishing Corporation
Journal of Oncology
Volume 2010, Article ID 414726, 4pages
Non-Hodgkin’s Lymphoma Reversal with Dichloroacetate
Dana F. Flavin1, 2
1Klinik im Alpenpark, Defreggerweg 2-6, Ringsee, 83707 Tegernsee, Germany
2Foundation for Collaborative Medicine and Research, 24 Midwood Drive, Greenwich, CT 06830, USA
Correspondence should be addressed to Dana F. Flavin, firstname.lastname@example.org
Received 4 June 2010; Accepted 23 July 2010
Academic Editor: Michael A. Carducci
Copyright © 2010 Dana F. Flavin. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In June 2007, a 48-year-old male patient, diagnosed with Stage 4 Non-Hodgkin’s Follicular Lymphoma (NHL), was treated for
3 months with conventional chemotherapy resulting in a complete remission. Almost one year later tumors returned in the
nasopharynx and neck lymph glands. Refusing all suggested chemotherapies, the patient began self-administering dichloroacetate
(DCA) 900 mg daily with a PET scan showing complete remission four months later. Since his last PET scan, May, 2009, he remains
tumor-free from continuous DCA usage.
Non-Hodgkin’s lymphoma (NHL), a cancer of the lymph
system that can start anywhere in body, aﬀects 400,000+
people in the United States with 66,000 new cases in
2009 . NHL often presents as a low grade fever with
sweating, swollen lymph nodes, general malaise, and fatigue.
Although it responds well to established therapies, including
chemotherapy and radiation , more aggressive newer
treatments are being developed, including chemotherapy
with whole body radiation followed by stem cell transplants
. While these treatments have resulted in complete remis-
sion in some patients , other patients, aware of the quality
of life compromises sustained with aggressive therapies ,
seek alternate avenues of treatment with professionals or
on their own, many of which are nonconventional or in
experimental stages. One such therapy is dichloroacetate
DCA is a by-product of water chlorination [6,7] that
inhibits aerobic glycolysis. It has been used in medicine
for over 30 years  as an investigational drug to treat
severe metabolic disorders such as diabetes and hypercholes-
acidosis in North American children . The bioavailability
 and pharmacokinetics ofDCAhavebeenwell
researched over several decades in adults , children [13,
14], and animals . As a medicinal, DCA is generally well
tolerated from dosages between 10 mg/Kg and 50 mg/Kg,
although prolonged exposure is associated with peripheral
neuropathy . Its activation of the pyruvate dehydroge-
nase enzyme (PDH) of the mitochondria decreases glycolysis
and reactivates glucose oxidation, a favorable approach to
ameliorate lactic acidosis .
Cancer cells predominantly utilize a system of glycolysis
for energy instead of the glucose oxidation used by healthy
cells. Cancer appears to be a form of intracellular lactic
acidosis caused by a block in the oxidation of glucose at
the level of PDH (pyruvate dehydrogenase). The glycolysis
metabolism of glucose increases cancer cells’ lactic acid and
reduces the intracellular pH  resulting major shifts in the
intracellular biochemistry. Aerobic glycolysis, known as the
“Warburg Eﬀect”, inactivates mitochondrial respiration
whichallowscancercellgrowth. DCA reverses this
glycolysis causing several major detrimental changes in the
cancer tumor cells.
First and foremost DCA inhibits pyruvate dehydrogenase
kinase (PDK). PDK blocks pyruvate dehydrogenase (PDH)
through its phosphorylation activity. When this kinase is
inhibited by DCA, the PDH is reactivated causing the
mitochondria to no longer be hyperpolarized, instead the
membrane and the mitochondria are depolarized, reacti-
vating the mitochondrial K+channels which then decreases
cytosolic K+. When PDH is inhibited in cancer cells by PDK,
an excess cytosolic K+occurs that inactivates the caspases
2Journal of Oncology
3 and 9, important factors in apoptosis. DCA reactivates
these caspases along with an increase in H2O2intracellularly,
allowing the release of cytochrome c from the mitochondria.
The release of cytochrome c is a major activating step for cell
apoptosis as it triggers the caspase cascade . The results
of DCA on cancers are seen both in vitro and in vivo. These
eﬀects are not seen in normal cells.
Dichloroacetate’s other major eﬀect on cancer cells is
the release of mitochondrial calcium (Ca++). The increase
of Ca++ in cancer cells is associated with the increase
and proliferation of transcription factors. Calcium also
activates ornithine decarboxylase, the rate limiting enzyme
in DNA synthesis , and the antiapoptosis factor NFAT
(nuclear factor of activated T lymphocytes) . When the
calcium decreases with the introduction of DCA, the cell
is further directed toward apoptosis and a decrease in cell
replication. In addition to DCA causing a major shift in the
mitochondria, cytoplasm, and cellular membrane , the
end eﬀect of DCA is a cell cycle arrest in the Gap 1 phase
(G1), which also increases apoptosis .
2. Materials and Method
After being successfully treated with six treatments of
Rituxan plus CHOP (cyclophosphamide, doxorubicin
hydrochloride, vincristine, and prednisolone) regime over
a period of three months in 2007, a positron emission
tomography (PET) scan showed a complete remission of the
NHL. With no further treatments by August 2008, the PET
showed his tumors returned in the nasopharynx and neck
lymph glands which presented with a low grade fever of 99.8,
sweating and fatigue.
The Non-Hodgkin’s Lymphoma patient refused conven-
tional therapy, instead personally obtaining dichloroacetate
(DCA) he began self-administering 900 mg daily at 10 mg/kg
in August 2008, adding a daily 750 mg of thiamine to
protect his nerves from toxicity [15,23]. Four months later a
PET scan showed complete remission (see Figure 2). He has
remained tumor-free on the continued regime of DCA and
thiamine since his last PET in May 2009. Monthly blood tests
are showing that all of his parameters are normal.
In August 2008, an NHL patient, who had been in remission
for almost a year after chemotherapy, complained of soreness
and tenderness in his neck area where protrusions were
visible upon examination. A PET was taken to investigate the
nature of the problem and the extent of lymph involvement.
Figure 1 shows that several new hypermetabolic foci
within the head and neck compatible with recurrent
lymphoma; new hypermetabolism in the right postlateral
aspect of the nasopharynx, measuring 3.2 ×2.2 cm; new
hypermetabolic adenopathy within the right neck involving
the right jugulo digastric region, right jugular chain, and
right posterior triangle extending to the base of the neck;
the largest node measuring approximately 1.9 ×1.9 cm;
several smaller hypermetabolic lymph nodes in the posterior
Figure 1: August 2008 PET scan.
Figure 2: December 2008 PET scan.
triangle extending to the base of the neck; a single focal
area of hypermetabolism within the left posterior triangle
corresponding to a small lymph node which measured 1.0
Four months after the patient’s daily self-medication with
750 mg of DCA, a PET scan showed no visible signs of
lymphoma. Symptoms disappeared after several weeks and
the results of the PET scan 4 months later in Figure 2 show
that the previously seen foci of abnormal activity within
the nasopharynx and neck had resolved; no abnormal foci
of metabolic activity were seen; no evidence of recurrent
The medical community is seeing more and more patients
who are seeking forms of therapy on their own with
varying results; some are deleterious and endangering while
others may prolong their lives but should still be done
under medical supervision. Understandably physicians fre-
quently cannot ethically advise or administer the use of the
patents’ preferences, leaving the patient to their own devices.
Although this case, and others anecdotally, resulted in a
successful outcome that might be explained by the existing
extensive research on the pharmacology and toxicology
of the dicholoroacetate treatment the patient chose, the
compound’s application in cancer patients is still under
investigation. We are presently looking at in vitro tumor
samples for testing sensitivity to DCA. We are also looking at
laboratory parameters for a possible laboratory correlation in
responders to speciﬁc enzyme levels as some patients’ cancers
respond positively or are resolved, DCA does not appear to
be not tumor type speciﬁc.
Journal of Oncology 3
Tumor cells preferentially use glycolysis to generate
adenosine triphosphate (ATP) even in the presence of
oxygen, a phenomenon known as aerobic glycolysis or
the “Warburg Eﬀect”. Pyruvate dehydrogenase (PDH),
a gate-keeping enzyme for the entry of pyruvate into
the mitochondrial tricarboxylic acid (TCA) cycle , is
inhibited in cancer cells by phosphorylation from the enzyme
pyruvate dehydrogenase kinase (PDK) . This inhibition
of PDH by PDK results in a shift from glucose oxidation
to glycolysis, which favors tumor growth . DCA has
been shown to block this phosphorylation by PDK at
the mitochondrial membrane level and decrease glycolysis
in favor of glucose oxidation. This return to a normal
metabolism of glucose allows for major changes including
++ intracellularly, and stabilization of the
mitochondria allowing a reactivation of caspases in cancer
cells leading to apoptosis .
The eﬀects of DCA, caused by reactivation of mitochon-
drial respiration, are not without complications although
it inexplicably seems to be predominantly limited to can-
cer cells while most normal cells remain unaﬀected .
A reversible, minimal nerve damage can be considerably
reduced by a daily thiamine intake of several hundred
milligrams for humans  and animals . The thiamine
amount varies from 50 mg/day to 100 mg/day depending on
whether it is administered orally or injected intramuscularly
Correcting mitochondrial dysfunction may be one of the
major future pharmacological targets for treating many dis-
eases, as many diseases’ mitochondrial dysfunction appears
to be a common pathological denominator. Lactic acidosis is
also seen as a complication in malaria  indicating mito-
chondrial involvement, and more recently Chronic Fatigue
Syndrome . DCA has also been shown to help consider-
ably in diabetes  and familial hypercholesterolemia .
A Non-Hodgkin’s lymphoma patient taking 10 mg/kg
[750 mg] of dichloroacetate daily of his own accord, had
a complete remission of his Non-Hodgkin’s lymphoma
cancer after four months that has continued to date by his
maintaining his DCA dosage in addition to taking 750 mg
thiamine to protect against the slight tingling and numbness
in the nerves of the ﬁngers and toes, without compromising
his quality of life or aﬀecting the treatment’s eﬃcacy.
Ignoring medical advice not to self-medicate he has con-
tinued his DCA/thiamine regimen, stating his concern that
discontinuing DCA may allow a recurrence of the disease.
There is too little data to draw absolute conclusions on
DCA’s usage for cancer. Controlled research needs to be
conducted for validation and conﬁrmation of DCA’s eﬃcacy
and maintenance levels in the spectrum of cancer therapies.
Conﬂict of Interests
The author reports no conﬂict of interests. The author alone
is responsible for the content and writing of the paper.
The help from Jimmy Xu at Carnegie Mellon University is
gratefully acknowledged. This work was supported by the
 Non-Hodgkin’s Lymphoma, National Cancer Institute, U.S.
National Institutes of Health, Rockville, Md, USA, May 2009,
 J. O. Armitage and D. L. Longo, “Malignancies of lymphoid
cells,” in Harrisons’s Principles of Internal Medicine,D.L.
Kasper, E. Braunwald, and A. S. Fauci, Eds., pp. 642–655,
McGraw Hill, New York, NY, USA, 16th edition, 2005.
overview of chemotherapy eﬀects in aggressive non-Hodgkin’s
lymphoma,” Acta Oncologica, vol. 40, no. 2-3, pp. 198–212,
 N. G. Mikhaeel, “Use of FDG-PET to monitor response to
chemotherapy and radiotherapy in patients with lymphomas,”
European Journal of Nuclear Medicine and Molecular Imaging,
vol. 33, no. 13, supplement 1, pp. 22–26, 2006.
 J. M. Donohue, H. Galal-Gorchev, W. Brattin, J. J. Liccione,
and K. B. Altshuler, Toxicological Review of Dichloroacetic Acid,
Integrated Risk Information System, U.S. EPA, Washington,
DC, USA, August 2003.
 I. R. Schultz and R. E. Shangraw, “Eﬀect of short-term drink-
ing water exposure to dichloroacetate on its pharmacokinetics
nd oral bioavailability in human volunteers: a stable isotope
study,” To x i c o log i c a l S c ienc e s , vol. 92, no. 1, pp. 42–50, 2006.
“Clinical pharmacology and toxicology of dichloroacetate,”
Environmental Health Perspectives, vol. 106, supplement 4, pp.
Harman, “Dichloroacetate in the treatment of lactic acidosis,”
Annals of Internal Medicine, vol. 108, no. 1, pp. 58–63, 1988.
 P. W. Stacpoole, “The pharmacology of dichloroacetate,”
Metabolism, vol. 38, no. 11, pp. 1124–1144, 1989.
tion of long-term treatment of children with congenital lactic
acidosis with dichloroacetate,” Pediatrics, vol. 121, no. 5, pp.
 S. H. Curry, A. Lorenz, P.-I. Chu, M. Limacher, and P. W.
Stacpoole, “(DCA) and oxalate following oral DCA doses,”
Biopharmaceutics and Drug Disposition, vol. 12, no. 5, pp. 375–
 M. Jia, B. Coats, M. Chadha et al., “Human kinetics of
orally and intravenously administered low-dose 1,2-(13)C-
dichloroacetate,” Journal of Clinical Pharmacology, vol. 46, no.
12, pp. 1449–1459, 2006.
 K. Berendzen, D. W. Theriaque, J. Shuster, and P. W. Stacpoole,
“Therapeutic potential of dichloroacetate for pyruvate dehy-
drogenase complex deﬁciency,” Mitochondrion,vol.6,no.3,
pp. 126–135, 2006.
 P. W. Stacpoole, D. S. Kerr, C. Barnes et al., “Controlled
clinical trial of dichloroacetate for treatment of congenital
lactic acidosis in children,” Pediatrics, vol. 117, no. 5, pp. 1519–
 P. W. Stacpoole, H. J. Harwood Jr., D. F. Cameron et
al., “Chronic toxicity of dichloroacetate: possible relation
to thiamine deﬁciency in rats,” Fundamental and Applied
Tox i c o lo g y , vol. 14, no. 2, pp. 327–337, 1990.
4Journal of Oncology
 P. W. Stacpoole, T. L. Kurtz, Z. Han, and T. Langaee, “Role
of dichloroacetate in the treatment of genetic mitochondrial
diseases,” Advanced Drug Delivery Reviews, vol. 60, no. 13-14,
pp. 1478–1487, 2008.
 O. Warburg, F. Wind, and E. Negelein, “¨
Uber den Stoﬀwechsel
von Tumoren im K¨
orper,” Journal of Molecular Medicine, vol.
5, no. 19, pp. 829–832, 1926.
etate (DCA) as a potential metabolic-targeting therapy for
cancer,” British Journal of Cancer, vol. 99, no. 7, pp. 989–994,
 S. Bonnet, S. L. Archer, J. Allalunis-Turner et al., “A
mitochondria-K+ channel axis is suppressed in cancer and
its normalization promotes apoptosis and inhibits cancer
growth,” Cancer Cell, vol. 11, no. 1, pp. 37–51, 2007.
 R. K. Boutwell, “Biochemical mechanism of tumor promo-
tion,” in Carcinogensis Mechanisms of Tumor Promotion and
pp. 29–58, Raven press, New York, NY, USA, 1978.
 J. Y. Y. Wong, G. S. Huggins, M. Debidda, N. C. Munshi, and
I. De Vivo, “Dichloroacetate induces apoptosis in endometrial
cancer cells,” Gynecologic Oncology, vol. 109, no. 3, pp. 394–
 W. Cao, S. Yacoub, K. T. Shiverick et al., “Dichloroacetate
(DCA) sensitizes both wild-type and over expressing bcl-2
prostate cancer cells in vitro to radiation,” Prostate, vol. 68, no.
11, pp. 1223–1231, 2008.
 L. Spruijt, R. K. Naviaux, K. A. McGowan et al., “Nerve
conduction changes in patients with mitochondrial diseases
treated with dichloroacetate,” Muscle and Nerve, vol. 24, no.
7, pp. 916–924, 2001.
 J. G. Pan and T. W. Mak, “Metabolic targeting as an anticancer
strategy: dawn of a new era?” Science’s STKE, vol. 2007, no.
381, p. pe14, 2007.
 S. Krishna, T. Agbenyega, B. J. Angus et al., “Pharmacokinetics
and pharmacodynamics of dichloroacetate in children with
lactic acidosis due to severe malaria,” QJM,vol.88,no.5,pp.
 S. Myhill, N. E. Booth, and J. McLaren-Howard, “Chronic
fatigue syndrome and mitochondrial dysfunction,” Interna-
tional Journal of Clinical and Experimental Medicine, vol. 2, no.
1, pp. 1–16, 2009.
 P. W. Stacpoole, G. W. Moore, and D. M. Kornhauser,
“Metabolic eﬀects of dichloroacetate in patients with diabetes
mellitus and hyperlipoproteinemia,” New England Journal of
Medicine, vol. 298, no. 10, pp. 526–530, 1978.
 G. W. Moore, L. L. Swift, and D. Rabinowitz, “Reduction of
serum cholesterol in two patients with homozygous familial
hypercholesterolemia by dichloroacetate,” Atherosclerosis, vol.
33, no. 3, pp. 285–293, 1979.